首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1994826

全球皮膚科藥物市場（2025-2035 年）

Dermatological Drugs Market: 2025 - 2035 Report

出版日期: 2025年12月31日 | 出版商:

SNS Research | 英文 273 Pages; 89 Tables & Figures | 商品交期: 請詢問到貨日

價格

簡介目錄

概括

全球皮膚科藥物市場正經歷強勁成長，這主要得益於皮膚疾病盛行率的上升、未被滿足的醫療需求以及對創新治療方法日益成長的需求。各公司正積極瞄準先前治療不足的多種疾病，生物製藥、生物相似藥和新型治療領域的突破正在再形成市場競爭格局。這些創新透過在銀屑病、異位性皮膚炎、脫髮症和皮膚癌等關鍵治療領域提供標靶性強、療效顯著的治療方法，重新定義了標準治療的概念。

皮膚科藥物仍是整個皮膚科市場中支出最大的細分領域，預計到2025年全球整體規模將達到5,28億美元。這些藥物繼續發揮重要的治療作用，涵蓋從痤瘡等常見皮膚病到銀屑病等複雜疾病的治療。儘管專利到期帶來了學名藥的競爭，但由於多種候選藥物正處於後期臨床試驗階段或即將上市，市場前景仍然強勁。

生物製藥正成為關鍵的成長驅動力，為慢性疾病患者和對傳統治療方法無反應的患者提供標靶治療標靶治療選擇。此外，藥物遞送系統的創新，特別是先進的局部平台和微針技術，正在提高藥物滲透性、耐受性和患者依從性，從而進一步推動市場擴張。

本報告對全球皮膚病藥物市場進行了全面分析，包括按地區和細分市場分類的市場規模和預測，以及對皮膚病藥物生態系統的詳細評估。

涵蓋的主題

皮膚科藥物生態系統
市場促進因素與障礙
皮膚疾病、應用領域及主要趨勢
主要藥物分類和主要皮膚科藥物分析
未來藥物開發平臺
皮膚科藥物傳輸技術
產業藍圖與價值鏈
生態系中 83 家主要企業的概況和策略，包括皮膚病藥物研發公司。
針對生態系統公司的策略建議
市場分析與預測（2025-2035）

範例圖：皮膚科在研藥物的研發階段細分

範例圖表：全球皮膚科產品支出（按細分市場分類）

預測性分割

治療類別

痤瘡和酒糟
脫髮症/毛髮疾病
皮膚炎
銀屑病
皮膚感染疾病
皮膚癌
其他疾病

藥物輸送途徑

局部的
口服
注射劑

製藥類型

OTC
處方

分銷管道

醫療機構/診所
零售藥房
網路藥房
直接面對消費者（D2C）

藥物分類

生物製藥

IL-23
IL-17
IL-4/13
TNF抑制劑
IL-12/23 及其他

低分子化合物

皮質類固醇
類視色素
Calcineurin抑制劑
PDE4抑制劑
JAK抑制劑
抗感染藥物
維生素D類似物
其他

基因療法和新治療方法

當地市場

亞太地區
歐洲
中東和非洲
北美洲
拉丁美洲和中美洲

全國市場

澳洲
巴西
加拿大
中國
埃及
法國
德國
希臘
印度
以色列
義大利
日本
墨西哥
荷蘭
波蘭
葡萄牙
俄羅斯
沙烏地阿拉伯
南非
韓國
西班牙
瑞士
台灣
土耳其
英國
美國

待覆蓋公司名單

3M
Abbott Laboratories
AbbVie
Abeona Therapeutics
AbGenomics Holding
AboundBio
Absci Corporation
Aclaris Therapeutics
Actelion Pharmaceuticals
Adaptimmune
AiCuris
Akouos
Akros Pharma
Alfasigma
Allergan
Almirall
AltruBio
Amgen
Amplyx Pharmaceuticals
Amryt Pharma
Anacor Pharmaceuticals
AnaptysBio
AndroScience Corporation
AnnJi Pharmaceutical
AOBiome
ApoPharma
Apotex
Arcutis Biotherapeutics
Arena Pharmaceuticals
Array BioPharma
Asana BioSciences
Astellas Pharma
AstraZeneca
Astria Therapeutics
Autotelic
Bausch Health Companies
Bayer Pharmaceuticals
Bill and Melinda Gates Foundation
Biocon Biologics
Biocon Generics
Biofrontera
BioGen
Biomedical Advanced Research and Development Authority（BARDA）
BioMimetix
BioOne Capital
BioRay Pharmaceutical
Biosintez
Bio-Thera Solutions
Boehringer Ingelheim
Botanix Pharmaceuticals
BPGbio
Bristol-Myers Squibb
Cadila Pharmaceuticals
Can-Fite BioPharma
Cantharidin Pharmaceuticals
Capella BioScience
Care Capital
Castle Creek Biosciences
Celgene
CellPoint
Celltrion
Cerbios-Pharma
Checkmate Pharmaceuticals
Chiesi Farmaceutici
Chugai Pharmaceutical
Cipher Pharmaceuticals
CKD Pharmaceuticals
Clarion Medical Technologies
Clinuvel Pharmaceuticals
Coherus BioSciences
Concert Pharmaceuticals
CorMedix
Cosette Pharmaceuticals
Cosmo Pharmaceuticals
CSL Behring
Cumberland Pharmaceuticals
Cutanea Life Sciences
Daewoong Pharmaceutical
Debiopharm
Dermata Therapeutics
Dermavant Sciences
DermBiont
Dermira
DFB Soria
DICE Therapeutics
Dow Pharmaceutical
Dr. Reddy's Laboratories
Durata Therapeutics
Dusa Pharmaceuticals
Eirion Therapeutics
Eli Lilly and Company
Elorac
Elsie Biotechnologies
EMD Serono
Encore Dermatology
Escalier Biosciences
Escient Pharmaceuticals
European Medicines Agency（EMA）
Evolus
Ewopharma
Exelixis
Eywa Pharma
F. Hoffmann-La Roche
FAES Farma
FDA
Fibrocell Science
G&E Herbal Biotechnology
Galapagos
Galderma
Galectin Therapeutics
Genentech
Gilead Sciences
Glenmark Pharmaceuticals
GSK（GlaxoSmithKline）
Gurnet Point
Gurnet Point Capital
Hallux
Hapten Sciences
Horizon Therapeutics
Hospira
Hoth Therapeutics
Huya Bioscience
Ichnos Glenmark Innovation
Ichnos Sciences
Immunocore
Immutep
Incyte Corporation
Innovation Pharmaceuticals
InSite Vision
Iovance Biotherapeutics
Ipsen
Janssen Pharmaceutical
Janssen Research & Development
Japan Tobacco
Jiangsu Hengrui Medicine
Johnson & Johnson
Journey Medical Corporation
Kiniksa Pharmaceuticals
Kintara Therapeutics
Krystal Biotech
Kyowa Kirin
Ladrome
LEO Pharma
Libertas Bio
Ligand Pharmaceuticals
Lipidor
Maruho
Mayne Pharma
MB Venture Partners
Meda Pharma
Melinta Therapeutics
Merck & Co
Merck KGaA
Merz Pharma
Microsoft
Moderna
MorphoSys
Mycovia Pharmaceuticals
Mylan
Nanology
Nestle Skin Health
Neumedicines
Nielsen BioSciences
Novartis
Novo Holdings
Oncolys Biopharma
Oncotelic
Ono Pharmaceutical
Optinose
OriCiro Genomics
Ortho Dermatologics
Paratek Pharmaceuticals
Pelthos Therapeutics
Pfizer
Philogen
Phio Pharmaceuticals
Photogen Technologies
Pierre Fabre
Pierre Fabre Laboratories
Poli Group
Polpharma Biologics
PolyMedix
Precigen
Prevail Therapeutics
Principia Biopharma
Priovant Therapeutics
Promius Pharma
ProQR Therapeutics
Proteologix
Protomer Technologies
Provectus Biopharmaceuticals
Pyxis Oncology
Qurient
Ralexar Therapeutics
Ranbaxy Laboratories
Rani Therapeutics
Regeneron Pharmaceuticals
Roche
Roivant Sciences
Samsung
Samsung Bioepis
Sandoz AG
Sanofi
SBI Biotech
Searchlight Pharma
Seattle Genetics
Sierra Oncology
Sinclair Pharma
Sol-Gel Technologies
Soligenix
Stiefel Laboratories
Sun Pharmaceutical Industries
Takeda
Takeda Oncology
Taro Pharmaceutical Industries
Teva Pharmaceutical Industries
The Proactiv Company
Timber Pharmaceuticals
Tioga Pharmaceuticals
Torii Pharmaceutical
Trillium Therapeutics
UCB Biopharma
UNION Therapeutics
University of Pennsylvania
Upjohn
URL Pharma
US WorldMeds
Valeant Pharmaceuticals
Vanda Pharmaceuticals
Vectans Pharma
Verrica Pharmaceuticals
VidacPharma
Villaris Therapeutics
Vyne Therapeutics
Zydus Group

簡介目錄

Synopsis:

The global dermatological drugs market is experiencing robust growth, driven by rising prevalence of skin disorders, persistent unmet medical needs, and increased demand for innovative therapies. Companies are strategically targeting diverse and previously underserved conditions, with breakthroughs across biologics, biosimilars, and novel therapeutic classes reshaping the competitive landscape. These innovations are delivering highly targeted, high-efficacy treatments across major therapeutic areas, including psoriasis, atopic dermatitis, alopecia areata, and skin cancer, and redefining standards of care.

Dermatological drugs remain the largest segment of spending within the broader dermatology market, projected to reach $52.8 billion globally by 2025. They continue to serve as the primary treatment option for both common conditions, such as acne, and complex diseases, including psoriasis. While patent expirations have introduced generic competition, the market outlook remains robust, supported by several late-stage and near-market drug candidates.

Biologics have emerged as a key growth driver, offering targeted treatment options for chronic conditions and providing targeted options for patients unresponsive to traditional therapies. Complementing this, innovations in drug delivery systems, particularly advanced topical platforms and microneedle technologies, are improving penetration, tolerability, and patient adherence, further supporting market expansion.

The "Dermatological Drugs Market: 2025 - 2035 - Opportunities, Challenges, Strategies & Forecasts" report presents an in-depth assessment of the dermatological drugs ecosystem including dermatological disorders, application areas, delivery technologies, key trends, market drivers, challenges, investment potential, leading therapies, drug development pipeline, opportunities, future roadmap, value chain, ecosystem player profiles and strategies.

The report covers market sizing & forecasts from 2025 - 2035 period which are segmented across seven therapeutic categories, three routes of administration, two drug types (OTC vs. Prescription), four distribution channels, three major drug classes (biologics, small molecules, gene & emerging therapies), and 26 leading countries across five regions.

Topics Covered:

The report covers the following topics:

Dermatological drugs ecosystem
Market drivers and barriers
Dermatological disorders, application areas and key trends
Analysis of key drug classes and leading dermatological drugs
Future drug development pipeline
Dermatological drug delivery technologies
Industry roadmap and value chain
Profiles and strategies of 83 leading ecosystem players, including dermatological drug developers
Strategic recommendations for ecosystem players
Market analysis and forecasts from 2025 till 2035

Sample Figure: Distribution of Dermatological Pipeline Candidates by Developmental Phase (%)

The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report and 2025 clinical pipeline dataset, profiling 216 drug candidates.

Key Findings:

The report has the following key findings.

Global dermatological drug spending is projected to reach approximately $52.8 billion in 2025, driven by sustained demand across inflammatory and chronic skin diseases.
Advanced biologics remain the primary growth engine, supported by high-impact approvals and label expansions across atopic dermatitis, urticaria, prurigo nodularis, and psoriasis.
IL-23 inhibitors (risankizumab, guselkumab) and dual-pathway IL-17 agents (bimekizumab) are setting the new standard for long-term, durable control of moderate-to-severe disease, reflecting the market's move toward deep, cytokine-specific immunology.
TYK2 inhibitors, led by deucravacitinib, are reshaping competitive dynamics by offering targeted efficacy with the convenience of oral dosing, positioning them as credible alternatives to injectables.
Innovation in topical agents such as JAK-based creams and PDE4 inhibitors continues to strengthen, improving localized therapeutic control and expanding treatment options for chronic inflammatory conditions.
The 2025 commercial entry of multiple ustekinumab biosimilars marks a structural shift in pricing and access, prompting originators to deploy aggressive lifecycle and payer-defense strategies.
Strategic acquisitions and alliances remain central to growth. Notable examples include J&J's acquisition of Proteologix, adding two bispecific antibodies for atopic dermatitis and reinforcing the industry-wide pivot toward precision immunology.

Key Questions Answered:

The report provides answers to the following key questions.

How big is the dermatological drugs opportunity?
What trends, challenges and barriers are influencing its growth?
How is the ecosystem evolving by segment and region?
What will the market size be in 2025 and at what rate will it grow?
Which countries and submarkets will see the highest percentage of growth?
What are the prospects of biosimilar drugs in dermatology?
What are the key drug delivery technologies being used in dermatological treatments?
How big is the market for psoriasis drugs?
Who are the key market players and what are their strategies?
How will patent expirations of innovator drugs impact the market?
What strategies should dermatological drug manufacturers adopt to remain competitive?